Biological E to make 50 million doses of Takeda’s dengue vaccine QDENGA

Takeda and Biological E Limited have partnered to manufacture up to 50 million doses per year of the dengue vaccine QDENGA, with the goal of delivering 100 million doses by 2030. The collaboration aims to make the vaccine widely accessible and combat dengue on a global scale.